CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC), a precision therapy company
focused on genomically defined cancers, rare diseases and cancer
immunotherapy, today announced that, effective on November 1, 2020, the Compensation Committee of
Blueprint Medicines' Board of Directors granted non-qualified stock
options to purchase an aggregate of 16,513 shares of its common
stock and an aggregate of 8,255 restricted stock units (RSUs)
to five new employees under Blueprint Medicines' 2020 Inducement
Plan.
The 2020 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously an employee or
non-employee director of Blueprint Medicines, as an inducement
material to such individual's entering into employment with
Blueprint Medicines, pursuant to Rule 5635(c)(4) of the NASDAQ
Listing Rules.
The options have an exercise price of $102.28 per share, which is equal to the closing
price of Blueprint Medicines' common stock on October 31, 2020. Each option will vest as to 25%
of the shares underlying such option on the first anniversary of
the grant date and as to an additional 1/48th of the shares
underlying the option monthly thereafter, in each case,
subject to each such employee's continued employment on each
vesting date. Each RSU will vest as to 25% of the shares underlying
the RSU award on the first anniversary of the grant date and as to
an additional 25% of the shares underlying the RSU award annually
thereafter, subject to each such employee's continued employment on
each vesting date. The options and RSUs are subject to the terms
and conditions of Blueprint Medicines' 2020 Inducement Plan, and
the terms and conditions of the stock option and RSU agreement
covering the grant.
About Blueprint Medicines
Blueprint Medicines is a precision therapy company striving
to improve human health. With a focus on genomically defined
cancers, rare diseases and cancer immunotherapy, we are developing
transformational medicines rooted in our leading expertise in
protein kinases, which are proven drivers of disease. Our uniquely
targeted, scalable approach empowers the rapid design and
development of new treatments and increases the likelihood of
clinical success. We have two approved precision therapies and are
currently advancing multiple investigational medicines in clinical
and pre-clinical development, along with a number of earlier-stage
research programs. For more information, visit
www.BlueprintMedicines.com and follow us on
Twitter (@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301165503.html
SOURCE Blueprint Medicines Corporation